Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 112 entries
Sorted by: Best Match Show Resources per page
Cancer Chemoprevention with Korean Angelica: Active Compounds, Pharmacokinetics, and Human Translational Considerations.

Current pharmacology reports

Lü J, Zhang J, Li L, Jiang C, Xing C.
PMID: 26623248
Curr Pharmacol Rep. 2015 Dec 01;1(6):373-381. doi: 10.1007/s40495-015-0033-y. Epub 2015 Apr 19.

No abstract available.

Cite
Lü J, Zhang J, Li L, et al. Cancer Chemoprevention with Korean Angelica: Active Compounds, Pharmacokinetics, and Human Translational Considerations. Curr Pharmacol Rep. 2015;1(6):373-381doi: 10.1007/s40495-015-0033-y.
Lü, J., Zhang, J., Li, L., Jiang, C., & Xing, C. (2015). Cancer Chemoprevention with Korean Angelica: Active Compounds, Pharmacokinetics, and Human Translational Considerations. Current pharmacology reports, 1(6), 373-381. https://doi.org/10.1007/s40495-015-0033-y
Lü, Junxuan, et al. "Cancer Chemoprevention with Korean Angelica: Active Compounds, Pharmacokinetics, and Human Translational Considerations." Current pharmacology reports vol. 1,6 (2015): 373-381. doi: https://doi.org/10.1007/s40495-015-0033-y
Lü J, Zhang J, Li L, Jiang C, Xing C. Cancer Chemoprevention with Korean Angelica: Active Compounds, Pharmacokinetics, and Human Translational Considerations. Curr Pharmacol Rep. 2015 Dec 01;1(6):373-381. doi: 10.1007/s40495-015-0033-y. Epub 2015 Apr 19. PMID: 26623248; PMCID: PMC4662572.
Copy Download .nbib Format: NLM
Challenges in the delivery of therapies to melanoma brain metastases.

Current pharmacology reports

Gampa G, Vaidhyanathan S, Resman BW, Parrish KE, Markovic SN, Sarkaria JN, Elmquist WF.
PMID: 28546917
Curr Pharmacol Rep. 2016 Dec;2(6):309-325. doi: 10.1007/s40495-016-0072-z. Epub 2016 Nov 09.

Brain metastases are a major cause of morbidity and mortality in patients with advanced melanoma. Recent approval of several molecularly-targeted agents and biologics has brought hope to patients with this previously untreatable disease. However, patients with symptomatic melanoma brain...

Cite
Gampa G, Vaidhyanathan S, Resman BW, et al. Challenges in the delivery of therapies to melanoma brain metastases. Curr Pharmacol Rep. 2016;2(6):309-325doi: 10.1007/s40495-016-0072-z.
Gampa, G., Vaidhyanathan, S., Resman, B. W., Parrish, K. E., Markovic, S. N., Sarkaria, J. N., & Elmquist, W. F. (2016). Challenges in the delivery of therapies to melanoma brain metastases. Current pharmacology reports, 2(6), 309-325. https://doi.org/10.1007/s40495-016-0072-z
Gampa, Gautham, et al. "Challenges in the delivery of therapies to melanoma brain metastases." Current pharmacology reports vol. 2,6 (2016): 309-325. doi: https://doi.org/10.1007/s40495-016-0072-z
Gampa G, Vaidhyanathan S, Resman BW, Parrish KE, Markovic SN, Sarkaria JN, Elmquist WF. Challenges in the delivery of therapies to melanoma brain metastases. Curr Pharmacol Rep. 2016 Dec;2(6):309-325. doi: 10.1007/s40495-016-0072-z. Epub 2016 Nov 09. PMID: 28546917; PMCID: PMC5440090.
Copy Download .nbib Format: NLM
"Curcumin, the King of Spices": Epigenetic Regulatory Mechanisms in the Prevention of Cancer, Neurological, and Inflammatory Diseases.

Current pharmacology reports

Boyanapalli SS, Kong AT.
PMID: 26457241
Curr Pharmacol Rep. 2015 Apr;1(2):129-139. doi: 10.1007/s40495-015-0018-x. Epub 2015 Jan 30.

Curcumin (diferuloylmethane), a polyphenolic compound, is a component of

Cite
Boyanapalli SS, Kong AT. "Curcumin, the King of Spices": Epigenetic Regulatory Mechanisms in the Prevention of Cancer, Neurological, and Inflammatory Diseases. Curr Pharmacol Rep. 2015;1(2):129-139doi: 10.1007/s40495-015-0018-x.
Boyanapalli, S. S., & Kong, A. T. (2015). "Curcumin, the King of Spices": Epigenetic Regulatory Mechanisms in the Prevention of Cancer, Neurological, and Inflammatory Diseases. Current pharmacology reports, 1(2), 129-139. https://doi.org/10.1007/s40495-015-0018-x
Boyanapalli, Sarandeep S S, and Kong, Ah-Ng. Tony. ""Curcumin, the King of Spices": Epigenetic Regulatory Mechanisms in the Prevention of Cancer, Neurological, and Inflammatory Diseases." Current pharmacology reports vol. 1,2 (2015): 129-139. doi: https://doi.org/10.1007/s40495-015-0018-x
Boyanapalli SS, Kong AT. "Curcumin, the King of Spices": Epigenetic Regulatory Mechanisms in the Prevention of Cancer, Neurological, and Inflammatory Diseases. Curr Pharmacol Rep. 2015 Apr;1(2):129-139. doi: 10.1007/s40495-015-0018-x. Epub 2015 Jan 30. PMID: 26457241; PMCID: PMC4596544.
Copy Download .nbib Format: NLM
Recent Advances in Development and Application of Physiologically-Based Pharmacokinetic (PBPK) Models: a Transition from Academic Curiosity to Regulatory Acceptance.

Current pharmacology reports

Jamei M.
PMID: 27226953
Curr Pharmacol Rep. 2016;2:161-169. doi: 10.1007/s40495-016-0059-9. Epub 2016 Apr 14.

There is a renewed surge of interest in applications of physiologically-based pharmacokinetic (PBPK) models by the pharmaceutical industry and regulatory agencies. Developing PBPK models within a systems pharmacology context allows separation of the parameters pertaining to the animal or...

Cite
Jamei M. Recent Advances in Development and Application of Physiologically-Based Pharmacokinetic (PBPK) Models: a Transition from Academic Curiosity to Regulatory Acceptance. Curr Pharmacol Rep. 2016;2:161-169doi: 10.1007/s40495-016-0059-9.
Jamei, M. (2016). Recent Advances in Development and Application of Physiologically-Based Pharmacokinetic (PBPK) Models: a Transition from Academic Curiosity to Regulatory Acceptance. Current pharmacology reports, 2161-169. https://doi.org/10.1007/s40495-016-0059-9
Jamei, Masoud. "Recent Advances in Development and Application of Physiologically-Based Pharmacokinetic (PBPK) Models: a Transition from Academic Curiosity to Regulatory Acceptance." Current pharmacology reports vol. 2 (2016): 161-169. doi: https://doi.org/10.1007/s40495-016-0059-9
Jamei M. Recent Advances in Development and Application of Physiologically-Based Pharmacokinetic (PBPK) Models: a Transition from Academic Curiosity to Regulatory Acceptance. Curr Pharmacol Rep. 2016;2:161-169. doi: 10.1007/s40495-016-0059-9. Epub 2016 Apr 14. PMID: 27226953; PMCID: PMC4856711.
Copy Download .nbib Format: NLM
Epigenetic Regulation by Sulforaphane: Opportunities for Breast and Prostate Cancer Chemoprevention.

Current pharmacology reports

Atwell LL, Beaver LM, Shannon J, Williams DE, Dashwood RH, Ho E.
PMID: 26042194
Curr Pharmacol Rep. 2015 Apr 01;1(2):102-111. doi: 10.1007/s40495-014-0002-x.

Sulforaphane (SFN) is a phytochemical derived from cruciferous vegetables that has multiple molecular targets and anti-cancer properties. Researchers have demonstrated several chemopreventive benefits of SFN consumption, such as reductions in tumor growth, increases in cancer cell apoptosis, and disruption...

Cite
Atwell LL, Beaver LM, Shannon J, et al. Epigenetic Regulation by Sulforaphane: Opportunities for Breast and Prostate Cancer Chemoprevention. Curr Pharmacol Rep. 2015;1(2):102-111doi: 10.1007/s40495-014-0002-x.
Atwell, L. L., Beaver, L. M., Shannon, J., Williams, D. E., Dashwood, R. H., & Ho, E. (2015). Epigenetic Regulation by Sulforaphane: Opportunities for Breast and Prostate Cancer Chemoprevention. Current pharmacology reports, 1(2), 102-111. https://doi.org/10.1007/s40495-014-0002-x
Atwell, Lauren L, et al. "Epigenetic Regulation by Sulforaphane: Opportunities for Breast and Prostate Cancer Chemoprevention." Current pharmacology reports vol. 1,2 (2015): 102-111. doi: https://doi.org/10.1007/s40495-014-0002-x
Atwell LL, Beaver LM, Shannon J, Williams DE, Dashwood RH, Ho E. Epigenetic Regulation by Sulforaphane: Opportunities for Breast and Prostate Cancer Chemoprevention. Curr Pharmacol Rep. 2015 Apr 01;1(2):102-111. doi: 10.1007/s40495-014-0002-x. PMID: 26042194; PMCID: PMC4450146.
Copy Download .nbib Format: NLM
Epigenetic Regulation of miRNAs and Breast Cancer Stem Cells.

Current pharmacology reports

Duru N, Gernapudi R, Eades G, Eckert R, Zhou Q.
PMID: 26052481
Curr Pharmacol Rep. 2015 Jun 01;1(3):161-169. doi: 10.1007/s40495-015-0022-1.

MicroRNAs have emerged as important targets of chemopreventive strategies in breast cancer. We have found that miRNAs are dysregulated at an early stage in breast cancer, in non-malignant Ductal Carcinoma In Situ. Many dietary chemoprevention agents can act by...

Cite
Duru N, Gernapudi R, Eades G, et al. Epigenetic Regulation of miRNAs and Breast Cancer Stem Cells. Curr Pharmacol Rep. 2015;1(3):161-169doi: 10.1007/s40495-015-0022-1.
Duru, N., Gernapudi, R., Eades, G., Eckert, R., & Zhou, Q. (2015). Epigenetic Regulation of miRNAs and Breast Cancer Stem Cells. Current pharmacology reports, 1(3), 161-169. https://doi.org/10.1007/s40495-015-0022-1
Duru, Nadire, et al. "Epigenetic Regulation of miRNAs and Breast Cancer Stem Cells." Current pharmacology reports vol. 1,3 (2015): 161-169. doi: https://doi.org/10.1007/s40495-015-0022-1
Duru N, Gernapudi R, Eades G, Eckert R, Zhou Q. Epigenetic Regulation of miRNAs and Breast Cancer Stem Cells. Curr Pharmacol Rep. 2015 Jun 01;1(3):161-169. doi: 10.1007/s40495-015-0022-1. PMID: 26052481; PMCID: PMC4452008.
Copy Download .nbib Format: NLM
Role of FXR in Liver Inflammation during Nonalcoholic Steatohepatitis.

Current pharmacology reports

Armstrong LE, Guo GL.
PMID: 28983452
Curr Pharmacol Rep. 2017 Apr;3(2):92-100. doi: 10.1007/s40495-017-0085-2. Epub 2017 Feb 21.

PURPOSE OF REVIEW: About 15-25% of patients with simple steatosis of non-alcoholic fatty liver disease progresses to non-alcoholic steatohepatitis (NASH), and the underlying mechanism for this progression has not been elucidated. NASH ultimately could progress to cirrhosis, an irreversible...

Cite
Armstrong LE, Guo GL. Role of FXR in Liver Inflammation during Nonalcoholic Steatohepatitis. Curr Pharmacol Rep. 2017;3(2):92-100doi: 10.1007/s40495-017-0085-2.
Armstrong, L. E., & Guo, G. L. (2017). Role of FXR in Liver Inflammation during Nonalcoholic Steatohepatitis. Current pharmacology reports, 3(2), 92-100. https://doi.org/10.1007/s40495-017-0085-2
Armstrong, Laura E, and Guo, Grace L. "Role of FXR in Liver Inflammation during Nonalcoholic Steatohepatitis." Current pharmacology reports vol. 3,2 (2017): 92-100. doi: https://doi.org/10.1007/s40495-017-0085-2
Armstrong LE, Guo GL. Role of FXR in Liver Inflammation during Nonalcoholic Steatohepatitis. Curr Pharmacol Rep. 2017 Apr;3(2):92-100. doi: 10.1007/s40495-017-0085-2. Epub 2017 Feb 21. PMID: 28983452; PMCID: PMC5624538.
Copy Download .nbib Format: NLM
Disease Progression Modeling: Key Concepts and Recent Developments.

Current pharmacology reports

Cook SF, Bies RR.
PMID: 28936389
Curr Pharmacol Rep. 2016 Oct;2(5):221-230. doi: 10.1007/s40495-016-0066-x. Epub 2016 Aug 15.

Disease modeling involves the use of mathematical functions to describe quantitatively the time course of disease progression. In order to characterize the natural progression of disease, these models generally incorporate longitudinal data for some biomarker(s) of disease severity or...

Cite
Cook SF, Bies RR. Disease Progression Modeling: Key Concepts and Recent Developments. Curr Pharmacol Rep. 2016;2(5):221-230doi: 10.1007/s40495-016-0066-x.
Cook, S. F., & Bies, R. R. (2016). Disease Progression Modeling: Key Concepts and Recent Developments. Current pharmacology reports, 2(5), 221-230. https://doi.org/10.1007/s40495-016-0066-x
Cook, Sarah F, and Bies, Robert R. "Disease Progression Modeling: Key Concepts and Recent Developments." Current pharmacology reports vol. 2,5 (2016): 221-230. doi: https://doi.org/10.1007/s40495-016-0066-x
Cook SF, Bies RR. Disease Progression Modeling: Key Concepts and Recent Developments. Curr Pharmacol Rep. 2016 Oct;2(5):221-230. doi: 10.1007/s40495-016-0066-x. Epub 2016 Aug 15. PMID: 28936389; PMCID: PMC5602534.
Copy Download .nbib Format: NLM
Interplay between Reactive oxygen Species and MicroRNAs in Cancer.

Current pharmacology reports

He J, Jiang BH.
PMID: 27284501
Curr Pharmacol Rep. 2016 Apr;2(2):82-90. doi: 10.1007/s40495-016-0051-4. Epub 2016 Feb 09.

Since both reactive oxygen species (ROS) production and microRNAs expression signature have been associated with tumor development, progression, metastasis and therapeutic response, it is important to understand the crosstalk between ROS and microRNAs. Indeed, growing evidence suggests a reciprocal...

Cite
He J, Jiang BH. Interplay between Reactive oxygen Species and MicroRNAs in Cancer. Curr Pharmacol Rep. 2016;2(2):82-90doi: 10.1007/s40495-016-0051-4.
He, J., & Jiang, B. H. (2016). Interplay between Reactive oxygen Species and MicroRNAs in Cancer. Current pharmacology reports, 2(2), 82-90. https://doi.org/10.1007/s40495-016-0051-4
He, Jun, and Jiang, Bing-Hua. "Interplay between Reactive oxygen Species and MicroRNAs in Cancer." Current pharmacology reports vol. 2,2 (2016): 82-90. doi: https://doi.org/10.1007/s40495-016-0051-4
He J, Jiang BH. Interplay between Reactive oxygen Species and MicroRNAs in Cancer. Curr Pharmacol Rep. 2016 Apr;2(2):82-90. doi: 10.1007/s40495-016-0051-4. Epub 2016 Feb 09. PMID: 27284501; PMCID: PMC4894750.
Copy Download .nbib Format: NLM
Pharmacometric Applications and Challenges in the Development of Therapeutic Antibodies in Immuno-Oncology.

Current pharmacology reports

Diao L, Meibohm B.
PMID: 30319936
Curr Pharmacol Rep. 2018 Aug;4(4):285-291. doi: 10.1007/s40495-018-0142-5. Epub 2018 May 03.

PURPOSE OF REVIEW: Monoclonal antibodies targeting key checkpoints in immune stimulatory pathways have over the last years become the mainstay of cancer immunotherapy. This article provides a brief review of the application and key impact of pharmacometrics and quantitative...

Cite
Diao L, Meibohm B. Pharmacometric Applications and Challenges in the Development of Therapeutic Antibodies in Immuno-Oncology. Curr Pharmacol Rep. 2018;4(4):285-291doi: 10.1007/s40495-018-0142-5.
Diao, L., & Meibohm, B. (2018). Pharmacometric Applications and Challenges in the Development of Therapeutic Antibodies in Immuno-Oncology. Current pharmacology reports, 4(4), 285-291. https://doi.org/10.1007/s40495-018-0142-5
Diao, Lei, and Meibohm, Bernd. "Pharmacometric Applications and Challenges in the Development of Therapeutic Antibodies in Immuno-Oncology." Current pharmacology reports vol. 4,4 (2018): 285-291. doi: https://doi.org/10.1007/s40495-018-0142-5
Diao L, Meibohm B. Pharmacometric Applications and Challenges in the Development of Therapeutic Antibodies in Immuno-Oncology. Curr Pharmacol Rep. 2018 Aug;4(4):285-291. doi: 10.1007/s40495-018-0142-5. Epub 2018 May 03. PMID: 30319936; PMCID: PMC6181227.
Copy Download .nbib Format: NLM
Emerging roles for clinical pharmacometrics in cancer precision medicine.

Current pharmacology reports

Nair S, Kong AT.
PMID: 30345221
Curr Pharmacol Rep. 2018 Jun;4(3):276-283. doi: 10.1007/s40495-018-0139-0. Epub 2018 Apr 20.

PURPOSE OF REVIEW: Although significant progress has been made in cancer research, there exist unmet needs in patient care as reflected by the 'Cancer Moonshot' goals. This review appreciates the potential utility of quantitative pharmacology in cancer precision medicine.RECENT...

Cite
Nair S, Kong AT. Emerging roles for clinical pharmacometrics in cancer precision medicine. Curr Pharmacol Rep. 2018;4(3):276-283doi: 10.1007/s40495-018-0139-0.
Nair, S., & Kong, A. T. (2018). Emerging roles for clinical pharmacometrics in cancer precision medicine. Current pharmacology reports, 4(3), 276-283. https://doi.org/10.1007/s40495-018-0139-0
Nair, Sujit, and Kong, Ah-Ng Tony. "Emerging roles for clinical pharmacometrics in cancer precision medicine." Current pharmacology reports vol. 4,3 (2018): 276-283. doi: https://doi.org/10.1007/s40495-018-0139-0
Nair S, Kong AT. Emerging roles for clinical pharmacometrics in cancer precision medicine. Curr Pharmacol Rep. 2018 Jun;4(3):276-283. doi: 10.1007/s40495-018-0139-0. Epub 2018 Apr 20. PMID: 30345221; PMCID: PMC6191048.
Copy Download .nbib Format: NLM
Sphingosine Kinases/Sphingosine 1-Phosphate Signaling in Hepatic Lipid Metabolism.

Current pharmacology reports

Kwong EK, Li X, Hylemon PB, Zhou H.
PMID: 29130028
Curr Pharmacol Rep. 2017 Aug;3:176-183. doi: 10.1007/s40495-017-0093-2. Epub 2017 Jun 20.

The ever-increasing prevalence of metabolic diseases such as dyslipidemia and diabetes in the western world continues to be of great public health concern. Biologically active sphingolipids, such as sphingosine 1-phosphate (S1P) and ceramide, are important regulators of lipid metabolism....

Cite
Kwong EK, Li X, Hylemon PB, et al. Sphingosine Kinases/Sphingosine 1-Phosphate Signaling in Hepatic Lipid Metabolism. Curr Pharmacol Rep. 2017;3:176-183doi: 10.1007/s40495-017-0093-2.
Kwong, E. K., Li, X., Hylemon, P. B., & Zhou, H. (2017). Sphingosine Kinases/Sphingosine 1-Phosphate Signaling in Hepatic Lipid Metabolism. Current pharmacology reports, 3176-183. https://doi.org/10.1007/s40495-017-0093-2
Kwong, Eric K, et al. "Sphingosine Kinases/Sphingosine 1-Phosphate Signaling in Hepatic Lipid Metabolism." Current pharmacology reports vol. 3 (2017): 176-183. doi: https://doi.org/10.1007/s40495-017-0093-2
Kwong EK, Li X, Hylemon PB, Zhou H. Sphingosine Kinases/Sphingosine 1-Phosphate Signaling in Hepatic Lipid Metabolism. Curr Pharmacol Rep. 2017 Aug;3:176-183. doi: 10.1007/s40495-017-0093-2. Epub 2017 Jun 20. PMID: 29130028; PMCID: PMC5678993.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 112 entries